Amgen Inc.
Amgen Reports Strong First Quarter 2026 Financial Results with Revenue Growth and Product Sales Performance
Summary
Amgen announced its first quarter 2026 financial results, reporting a 6% increase in total revenues to $8.6 billion. Product sales grew 4%, driven by 9% volume growth, partially offset by lower net selling price and inventory levels. Sixteen products delivered at least double-digit sales growth, and seventeen products achieved annual sales of over $1 billion. Non-GAAP earnings per share increased 5% to $5.15, and the company generated $1.5 billion in free cash flow. Amgen also provided updates on its pipeline, including Phase 3 studies for several products.
Profitelligence Alerts
Get alerts for AMGN
Be first to know when Amgen Inc. files with the SEC.
Filing Categories
Advertisement
About Amgen Inc.
Amgen Inc. is a leading biotechnology company focused on the discovery, development, manufacturing, and marketing of human therapeutics. Established in 1980 and headquartered in Thousand Oaks, California, Amgen is recognized for pioneering biologic treatments and having a robust pipeline that targets critical areas like oncology, cardiovascular, and nephrology. The company has harnessed advanced technology platforms and deep scientific expertise to deliver innovative medicines such as Neulasta, Enbrel, and Prolia, which are significant players in the health care sector. Amgen serves markets globally, impacting the biotech industry by transforming the ways diseases are treated. Its investment in state-of-the-art manufacturing facilities and research makes it a significant entity in the pharmaceutical landscape, contributing to long-term health care solutions.
Official SEC Documents
Advertisement